Real-world experiences of migraine patients on Erenumab: a Kuwait single center cohort

References

• Pescador Ruschel MA, De Jesus O. Migraine headache. Treasure Island (FL): StatPearls Publishing; 2023.
   Google Scholar
• Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache. 2018;58(S1):4–16. doi: 10.1111/head.13300
   PubMedGoogle Scholar
• Schramm SH, Obermann M, Katsarava Z, et al. Epidemiological profiles of patients with chronic migraine and chronic tension-type headache. J Headache Pain. 2013;14(1):1–8. doi: 10.1186/1129-2377-14-40
   PubMedGoogle Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45(s1):S3–S13. doi: 10.1111/j.1526-4610.2005.4501001.x
   PubMedGoogle Scholar
• Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–1259. doi: 10.1016/S0140-6736(17)32154-2
   PubMed Web of Science ®Google Scholar
• Burch RC, Loder S, Loder E, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34. doi: 10.1111/head.12482
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Hagen K, Linde M, et al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):1–17. doi: 10.1186/s10194-022-01402-2
   PubMed Web of Science ®Google Scholar
• Al Jumah M, Awada A, Al Azzam S, et al. Headache syndromes amongst schoolchildren in Riyadh. Headache. 2002;42(4):281–286. doi: 10.1046/j.1526-4610.2002.02081.x
   PubMed Web of Science ®Google Scholar
• El-Metwally A, Toivola P, Alahmary K, et al. The epidemiology of migraine headache in Arab countries: a systematic review. Sci World J. 2020;2020:1–11. doi: 10.1155/2020/4790254
   Google Scholar
• Al-Hashel JY, Ahmed SF, Alroughani R. Prevalence of primary headache disorders in Kuwait. Neuroepidemiology. 2017;48(3–4):138–146. doi: 10.1159/000478892
   PubMed Web of Science ®Google Scholar
• Buse DC, Lipton RB. Global perspectives on the burden of episodic and chronic migraine. Cephalalgia. 2013;33(11):885–890. doi: 10.1177/0333102413477736
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17–20. doi: 10.1186/s10194-018-0846-2
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):954–976. doi: 10.1016/S1474-4422(18)30322-3
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78(17):1337–1345. doi: 10.1212/WNL.0b013e3182535d20
   PubMed Web of Science ®Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20. doi: 10.1111/head.12499
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622. doi: 10.1152/physrev.00034.2015
   PubMed Web of Science ®Google Scholar
• King CT, V GC, Hu S-Y, et al. Discovery of the migraine prevention therapeutic aimovig (erenumab), the first FDA-approved antibody against a G-Protein-coupled receptor. ACS Pharmacol Transl Sci. 2019;2(6):485–490. doi: 10.1021/acsptsci.9b00061
   PubMedGoogle Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434. doi: 10.1016/S1474-4422(17)30083-2
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132. doi: 10.1056/NEJMoa1705848
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037. doi: 10.1177/0333102418759786
   PubMed Web of Science ®Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. doi: 10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Olesen J. International classification of headache disorders. Lancet Neurol. 2018;17(5):396–397. doi: 10.1016/S1474-4422(18)30085-1
   PubMed Web of Science ®Google Scholar
• The Whoqol Group. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 1998;46(12):1569–1585. doi: 10.1016/S0277-9536(98)00009-4
   PubMed Web of Science ®Google Scholar
• Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382–390. doi: 10.1016/S1474-4422(16)00019-3
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–2287. doi: 10.1016/S0140-6736(18)32534-0
   PubMed Web of Science ®Google Scholar
• Alsaadi T, Noori S, Varakian R, et al. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE. BMC neurol. 2022;22(1):1–11. doi: 10.1186/s12883-022-02710-5
   PubMed Web of Science ®Google Scholar
• Bomtempo FF, Rocha RB, Cenci GI, et al. Long-term safety and effectiveness of erenumab in patients with migraine: a systematic review and single-arm meta-analysis. Clin Drug Investig. 2023;43(1):45–59. doi: 10.1007/s40261-022-01230-x
   PubMed Web of Science ®Google Scholar
• Gui T, Li H, Zhu F, et al. Different dosage regimens of erenumab for the treatment of migraine: a systematic review and meta‐analysis of the efficacy and safety of randomized controlled trials. Headache. 2022;62(10):1281–1292. doi: 10.1111/head.14423
   PubMed Web of Science ®Google Scholar